

# News story: £30 million of funding to tackle antimicrobial resistance

The funding will be delivered through 4 new projects as part of the Global AMR Innovation Fund (GAMRIF):

- £20 million to the [Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator](#) – a non-profit international partnership supporting research on the most dangerous drug-resistant bacteria. This commitment will support scientific research around the world to develop new vaccines and alternatives-to-antibiotics against drug-resistant bacterial infections in humans
- £5 million for a new bilateral partnership with Argentina supporting research to tackle AMR in agriculture and the impact on the environment – delivered via the Biotechnology and Biological Sciences Research Council and the Natural Environment Research Council. The bilateral partnership will be delivered and matched-funded, on a resource basis, by the National Scientific and Technical Research Council in Argentina
- £5 million invested in the [Foundation for Innovative New Diagnostics](#) (FIND) – a global non-profit organisation aimed at the development, evaluation and delivery of high-quality affordable diagnostic tests for poverty-related diseases. This funding will support FIND's work to enhance the impact of diagnostic tools, in particular the connectivity of point-of-care diagnostics for AMR surveillance
- £1 million invested in the [Global Antibiotic Research and Development Partnership](#) (GARDP) – a non-profit research and development initiative addressing global public health needs by developing, delivering and assuring sustainable access of new or improved antibiotic treatments. This funding will support GARDP's programme on sexually transmitted infections, focusing on the development of a new antibiotic for drug-resistant gonorrhea

These projects are funded by UK aid and will primarily benefit people in low- and middle-income countries, where the burden of infection is greatest.

AMR occurs when microbes, including bacteria, viruses, fungi and parasites, no longer respond to the drugs that would normally kill them, such as antibiotics. This leaves us powerless to treat what are normally routine infections. It is estimated that 5,000 deaths are caused every year in the UK because antibiotics no longer work for some infections.

Professor Dame Sally Davies, England's Chief Medical Officer, said:

Today's announcement is further evidence of the UK collaborating with international partners to lead global efforts to tackle AMR. The GAMRIF investments aim to protect the world's most vulnerable and tackle AMR where the burden of infection is greatest.

I am pleased that the UK will be working in partnership with a range of leading organisations to deliver vital research activities across the OneHealth spectrum – together this represents a formidable force against the threat of superbugs.

Health and Social Care Secretary Jeremy Hunt said:

Antimicrobial resistance is no longer a threat of the future – it is a problem here and now, and one that is killing hundreds of thousands of people across the world each year. This new investment cements our commitment to world-leading new research to tackle AMR on a global scale, and these innovative projects have the potential to develop real solutions and save lives.

GAMRIF's other projects include a [UK-China AMR collaboration](#) and [InnoVet-AMR](#), with the Canadian International Development Research Centre.